Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERICA – Cerebrolysin in CADASIL
2024-513828-42-00Phase 2Authorised
- Sponsor
- EVER Pharma
- Start
- Sep 2024
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cerebrolysin in cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (2 arms), sponsored by EVER Pharma. Primary endpoint: Primary multidimensional outcome ensemble. Planned start Sep 2024; status: authorised.
02
Drugs
cerebrolysin
03
Conditions
cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL)
Beyond the preview
Go deeper on 2024-513828-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513828-42-00.